[go: up one dir, main page]

WO2000042063A3 - Peptide zur inhibierung von hbv-core-proteinen - Google Patents

Peptide zur inhibierung von hbv-core-proteinen Download PDF

Info

Publication number
WO2000042063A3
WO2000042063A3 PCT/DE2000/000140 DE0000140W WO0042063A3 WO 2000042063 A3 WO2000042063 A3 WO 2000042063A3 DE 0000140 W DE0000140 W DE 0000140W WO 0042063 A3 WO0042063 A3 WO 0042063A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
core proteins
inhibiting hbv
hbv core
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2000/000140
Other languages
English (en)
French (fr)
Other versions
WO2000042063A2 (de
Inventor
Karin Butz
Felix Hoppe-Seyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Priority to EP00908930A priority Critical patent/EP1140995A2/de
Priority to JP2000593630A priority patent/JP2002534111A/ja
Publication of WO2000042063A2 publication Critical patent/WO2000042063A2/de
Publication of WO2000042063A3 publication Critical patent/WO2000042063A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft Peptide, die sich zur Inhibierung von HBV Core-Proteinen eignen, sie kodierende DNAs und die Verwendung beider, insbesondere zur Hemmung der HBV-Replikation.
PCT/DE2000/000140 1999-01-13 2000-01-12 Peptide zur inhibierung von hbv-core-proteinen Ceased WO2000042063A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00908930A EP1140995A2 (de) 1999-01-13 2000-01-12 Peptide zur inhibierung von hbv-core-proteinen
JP2000593630A JP2002534111A (ja) 1999-01-13 2000-01-12 Ｈｂｖコアタンパク質阻害用ペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19901009.9 1999-01-13
DE19901009A DE19901009A1 (de) 1999-01-13 1999-01-13 Peptide zur Inhibierung von HBV-Core-Proteinen

Publications (2)

Publication Number Publication Date
WO2000042063A2 WO2000042063A2 (de) 2000-07-20
WO2000042063A3 true WO2000042063A3 (de) 2000-12-14

Family

ID=7894120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/000140 Ceased WO2000042063A2 (de) 1999-01-13 2000-01-12 Peptide zur inhibierung von hbv-core-proteinen

Country Status (4)

Country Link
EP (1) EP1140995A2 (de)
JP (1) JP2002534111A (de)
DE (1) DE19901009A1 (de)
WO (1) WO2000042063A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859518B2 (en) 2004-04-22 2014-10-14 Regado Biosciences, Inc. Modulators of coagulation factors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296305B2 (en) 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
PT1401853E (pt) 2001-05-25 2010-12-07 Univ Duke Modulador de oligonucleotídeos
CN102268066B (zh) * 2010-06-01 2014-01-22 雷海民 抗乙肝病毒寡肽及其衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016727D0 (en) * 1990-07-31 1990-09-12 Clonit Spa Amino acid residue sequence of hepatitis b core antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL R. DYSON ET AL.: "Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus", PROC.NATL.ACAD.SCI., vol. 92, 1995, pages 2194 - 8, XP002141206 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859518B2 (en) 2004-04-22 2014-10-14 Regado Biosciences, Inc. Modulators of coagulation factors

Also Published As

Publication number Publication date
WO2000042063A2 (de) 2000-07-20
DE19901009A1 (de) 2000-07-20
JP2002534111A (ja) 2002-10-15
EP1140995A2 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
AU2001292757A1 (en) Modified selex processes without purified protein
ZA983496B (en) Methods for processing activated protein C.
AU2001271744A1 (en) Leucine-rich repeat proteins, zlrr7, zlrr8 and zlrr9
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
AU6114700A (en) Novel system for the sequential, directional cloning of multiple dna sequences
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
AU2001244609A1 (en) Novel protein, dna thereof and process for producing the same
ZA200205408B (en) Process for the preparation of peptides.
AU2001282037A1 (en) Proton-translocating retinal protein
WO2000042063A3 (de) Peptide zur inhibierung von hbv-core-proteinen
AU2002217863A1 (en) Homing peptide multimers, their preparation and uses
AU2001265213A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002215386A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU3556800A (en) Expression of dna or proteins in (c. elegans)
WO1998017827A3 (en) Compositions and methods using eukaryotic rad52
AU2001295580A1 (en) Nucleotide sequences which code for the dep67 protein
AU2001286687A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2002326641A1 (en) Nucleic-acid associated proteins
AU2001290872A1 (en) Isolated human kinase proteins, nucleic acid molecules and uses thereof
ZA200202823B (en) Self-cleaving RNA sequences and their use for the control of protein synthesis.
AU2002232599A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2001272910A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 593630

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000908930

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09889135

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000908930

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000908930

Country of ref document: EP